Literature DB >> 15350335

Ocular complications after iodine brachytherapy for large uveal melanomas.

Ilkka Puusaari1, Jorma Heikkonen, Tero Kivelä.   

Abstract

PURPOSE: To evaluate anterior and posterior segment complications and their management after iodine 125 plaque brachytherapy (IBT) for large uveal melanoma.
DESIGN: Retrospective nonrandomized interventional study. PARTICIPANTS: Ninety-six patients with a large uveal melanoma according to the Collaborative Ocular Melanoma Study criteria.
METHODS: The patients underwent primary IBT (median dose to tumor apex, 87 Gy). The median tumor height and diameter were 10.7 mm (range, 4.5-16.8) and 16.5 mm (range, 7.3-25.0), respectively, and the median follow-up time was 3.5 years (range, 0.3-10.4). Cumulative incidence analysis and competing risks regression were used to analyze the time to individual complications and to identify risk factors. Death and secondary enucleation were analyzed as competing risks. MAIN OUTCOME MEASURES: Cataract, iris neovascularization, glaucoma, maculopathy, optic neuropathy, vitreous hemorrhage, and persistent exudative retinal detachment (RD).
RESULTS: The 5-year cumulative incidences of cataract, iris neovascularization, and glaucoma were 69% (95% confidence interval [CI], 57%-78%), 62% (95% CI, 50%-71%), and 60% (95% CI, 48%-70%), respectively. Posterior segment complications were less common. The 5-year incidences of maculopathy and optic neuropathy were 52% (95% CI, 35%-65%) and 46% (95% CI, 30%-61%), and those of vitreous hemorrhage and persistent RD were 36% (95% CI, 23%-48%) and 25% (95% CI, 15%-36%), respectively. More than 80% of complications were diagnosed within 3 years. Cataract was the earliest complication to appear. Except for cataract, the cumulative incidence of dying without developing a particular complication was 0.24 to 0.62 times that of first developing the complication. Increasing tumor height, which correlates to increasing doses to adjacent tissues, was associated with time to cataract (P = 0.017), iris neovascularization (P = 0.087), and RD (P = 0.046). Maculopathy and optic neuropathy were associated primarily with distance to the fovea (P = 0.015) and optic disc (P = 0.015), respectively. Of 57 patients with cataract, 47% underwent cataract extraction, and 12% of 51 patients with glaucoma were treated with cyclophotocoagulation. The prevalences of cataract, elevated intraocular pressure, and RD were 43%, 39%, and 13%, respectively, at 5 years.
CONCLUSIONS: The frequency with which ocular complications develop after IBT is notably influenced by competing risks. Cumulative incidence and prevalence analysis provide realistic estimates for patient counseling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15350335     DOI: 10.1016/j.ophtha.2004.03.027

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  16 in total

1.  Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumour height.

Authors:  Ilkka Puusaari; Bertil Damato; Tero Kivelä
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-18       Impact factor: 3.117

2.  Long-term visual acuity results of treated and untreated radiation retinopathy (an AOS thesis).

Authors:  James L Kinyoun
Journal:  Trans Am Ophthalmol Soc       Date:  2008

3.  Iris melanoma: factors predictive of post-management secondary glaucoma in 271 cases at a Single Ocular Oncology Centre.

Authors:  Aakriti Garg Shukla; Sarangdev Vaidya; Antonio Yaghy; Maura Di Nicola; Swathi Kaliki; Enzo Fulco; Jonathan S Myers; Jerry A Shields; Carol L Shields
Journal:  Eye (Lond)       Date:  2022-04-05       Impact factor: 3.775

4.  Radiation Retinopathy 47 Years following Brachytherapy for Retinoblastoma.

Authors:  Claudine Bellerive; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2017-11-03

Review 5.  [Uveal and iridociliary melanomas in young patients : A retrospective analysis of 57 cases].

Authors:  L J Heyer; C Metz; D Flühs; C M Heyer; N Bornfeld
Journal:  Ophthalmologe       Date:  2016-12       Impact factor: 1.059

6.  Iodine-125 Episcleral Plaque Brachytherapy for AJCC T4 Posterior Uveal Melanoma: Clinical Outcomes in 158 Patients.

Authors:  Benjamin A King; Caroline Awh; Brad T Gao; Jiajing Wang; Mehmet Kocak; Vanessa M Morales-Tirado; Matthew T Ballo; Matthew W Wilson
Journal:  Ocul Oncol Pathol       Date:  2019-01-10

7.  Quantitative OCT Angiography Evaluation of Peripapillary Retinal Circulation after Plaque Brachytherapy.

Authors:  Alison H Skalet; Liang Liu; Christina Binder; Audra K Miller; Jie Wang; David J Wilson; Richard Crilly; Charles R Thomas; Arthur Y Hung; David Huang; Yali Jia
Journal:  Ophthalmol Retina       Date:  2018-03

8.  Novel low-kVp beamlet system for choroidal melanoma.

Authors:  Carlos Esquivel; Clifton D Fuller; Robert G Waggener; Adrian Wong; Martin Meltz; Melissa Blough; Tony Y Eng; Charles R Thomas
Journal:  Radiat Oncol       Date:  2006-09-11       Impact factor: 3.481

9.  Irreversible electroporation of human primary uveal melanoma in enucleated eyes.

Authors:  Yossi Mandel; Shlomi Laufer; Michael Belkin; Boris Rubinsky; Jacob Pe'er; Shahar Frenkel
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

10.  Nomogram for predicting radiation maculopathy in patients treated with Ruthenium-106 plaque brachytherapy for uveal melanoma.

Authors:  Luca Tagliaferri; Monica Maria Pagliara; Carlotta Masciocchi; Andrea Scupola; Luigi Azario; Gabriela Grimaldi; Rosa Autorino; Maria Antonietta Gambacorta; Antonio Laricchiuta; Luca Boldrini; Vincenzo Valentini; Maria Antonietta Blasi
Journal:  J Contemp Brachytherapy       Date:  2017-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.